Advancing peptides for the treatment of rare endocrine and metabolic disorders
We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
PROGRAMS
AZP-3601
Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.
AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3800
We are testing a series of novel, highly potent, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.
AZP-3404
AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.
LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.
Press Releases & Recent News
Amolyt Pharma Announces Appointment of Two Directors
Download a PDF copy of this press release: EN FR Elisabeth Svanberg, M.D., Ph.D. brings extensive experience in the development …
Amolyt Pharma Announces Hiring of Louis J. Arcudi III as Chief Financial Officer
Download a PDF copy of this press release: EN FR Appointment of US-based CFO adds more than 20 years of …